Skip to main content

Delay to formalin fixation effect on HER2 test in breast cancer by dual-color silver-enhanced in situ hybridization (Dual-ISH).

Khoury T, Liu Q, Liu S

Publication: Appl Immunohistochem Mol Morphol (2014) • Vol 22 • Page 688-95PMID: 24992176View on PubMed

Purpose

The paper examined whether cold ischemia time affects the number of human epidermal growth factor receptor 2 (HER2)- or chromosome enumeration probe 17 (CEP17)-positive cells or the intensity of in situ hybridization (ISH) signal in formalin-fixed, paraffin-embedded (FFPE) breast cancer specimens.

Conclusion

HER2, CEPT17 and HER2/CEPT17 ratio did not differ among FFPE breast tumor specimens subjected to different cold ischemia times when analyzed by dual ISH. However, cold ischemia resulted in ISH signal loss (p<0.001), with the largest decrease in the mean number of cells that experienced a loss of ISH signal occurring between 1 and 2 hours (11% vs. 21%, respectively). The authors note that breast tumors subjected to a cold ischemia time of 4 to 8 h, which demonstrated signal loss in 24% and 28% of cells, respectively, may not meet the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP)'s eligibility criteria of <25% .  Artifacts including nuclear bubbling and background haze were observed in specimens from 4 of the 10 cases examined, and were significantly associated with cold ischemia time (p=0.009). The authors advise limiting cold ischemia of breast tumor specimens to 1 h or less.

Studies (1)

Purpose

The study examined whether cold ischemia time affects the number of HER2- or CEP17-positive cells or the intensity of ISH signal in FFPE breast cancer specimens. Breast invasive ductal carcinoma specimens were procured via lumpectomy from 10 patients, processed immediately and fixed as soon as possible (within 2-5 min) or placed in 0.9% NaCl and stored for varying durations (10 min-8 h) at room temperature or at 4°C overnight.  Specimens were fixed in 10% neutral buffered formalin for 12-32 h and were uniformly processed. FFPE specimens were then assembled into tissue microarrays using 0.6 mm cores prior to dual in situ hybridization for HER2 and CEPT17.

Summary of Findings

HER2, CEPT17 and HER2/CEPT17 ratio did not differ among FFPE breast tumor specimens subjected to different cold ischemia times when analyzed by dual ISH; however, the mean number of cells that lost signal increased as cold ischemia progressed (p<0.001). While declines in the number of cells with an observable ISH signal due to cold ischemia were observed between 1 and 8 hours, the largest difference was observed between 1 and 2 hours (11% vs. 21%, respectively). The authors note that breast tumors subjected to a cold ischemia time of 4 to 8 h, which demonstrated signal loss in 24% and 28% of cells, respectively, may not meet ASCO-CAP eligibility criteria specifying staining in a minimum of  25% of cells.  Artifacts that included nuclear bubbling and background haze were observed in specimens from 4 of the 10 cases examined, and were significantly associated with cold ischemia time (p=0.009). The authors advise limiting cold ischemia of breast tumor specimens to 1 h or less.

  • Biospecimens

    TissueBreast
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    DNAIn situ hybridization
    DNATissue microarray
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionCold ischemia time
    0 min
    1 h
    10 min
    2 h
    30 min
    4 h
    8 h
    overnight at 4 degrees C
    In situ hybridization SpecificTargeted nucleic acid
    CEPT17
    HER2